Kenvue Inc. is a leading global consumer health company, recognized as the world's largest pure-play consumer health company by revenue, with $15.4 billion in net sales in 2023 . The company operates through three main business segments: Self Care, Skin Health and Beauty, and Essential Health . Kenvue's portfolio includes products for pain care, cough, cold, and allergy, as well as face and body care, oral care, and baby care, featuring iconic brands like Tylenol®, Neutrogena®, and Listerine® . The company's global operations span over 165 countries, with approximately half of its net sales generated outside North America .
- Skin Health and Beauty - Focuses on face and body care, and hair, sun, and other products, featuring brands such as Neutrogena® and Aveeno®.
- Self Care - Offers products for pain care, cough, cold, and allergy, as well as digestive health, smoking cessation, and eye care, with brands like Tylenol®, Motrin®, and Nicorette®.
- Essential Health - Covers oral care, baby care, and other essential health products, including brands like Listerine® and Johnson’s®.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Thibaut Mongon ExecutiveBoard | Chief Executive Officer and Director | Board Member of The Consumer Goods Forum; Member of the Business Roundtable | CEO of Kenvue since May 2023, previously EVP and Worldwide Chairman of Consumer Health at Johnson & Johnson. Extensive experience in consumer health and business strategy. | View Report → |
Bernardo Tavares Executive | Chief Technology & Data Officer | Member of MIT Center for Information Systems Research Data Research Advisory Board; Member of Hispanic Information Technology Executive Council | Chief Technology & Data Officer since May 2023, previously CIO, Consumer Health at Johnson & Johnson, and held IT leadership roles at Unilever and IBM. | |
Carlton Lawson Executive | Group President, EMEA & Latin America | None mentioned | Group President since January 2024, previously Company Group Chairman, EMEA, Consumer Health at Johnson & Johnson, and held leadership roles at GSK and Pfizer. | |
Caroline Tillett Executive | Chief Scientific Officer | None mentioned | Chief Scientific Officer since May 2023, previously Global Head, R&D, Consumer Health at Johnson & Johnson, and VP of Consumer R&D at GSK. | |
Charmaine England Executive | Chief Growth Officer | None mentioned | Chief Growth Officer since January 2024, previously Area Managing Director for UK & Northern Europe at Kenvue and held leadership roles at Johnson & Johnson, Pact Group, Unilever, and Lion. | |
Ellie Bing Xie Executive | Group President, Asia Pacific | None mentioned | Group President since May 2023, previously Company Group Chairman, Asia Pacific, Consumer Health at Johnson & Johnson, and held leadership roles at Kellogg, Kodak, Gillette, and P&G. | |
Luani Alvarado Executive | Chief People Officer | None mentioned | CPO of Kenvue since May 2023, previously held senior HR roles at Johnson & Johnson, Bristol-Myers Squibb, and Dow Chemical. | |
Matthew Orlando Executive | General Counsel | None mentioned | General Counsel since May 2023, previously held senior legal leadership roles at Johnson & Johnson, including General Counsel, Consumer Health. | |
Meredith Stevens Executive | Chief Operations Officer | Advisory Board Member at Smithsonian Science Education Center | COO of Kenvue since May 2023, previously Worldwide VP, Consumer Health Supply Chain at Johnson & Johnson, and held leadership roles at Newell Rubbermaid, Tyco, Bertelsmann, Knoll, and GE. | |
Paul Ruh Executive | Chief Financial Officer | None mentioned | CFO of Kenvue since May 2023, previously CFO of Consumer Health at Johnson & Johnson and held leadership roles at PepsiCo and McKinsey & Company. | |
Betsy D. Holden Board | Director | Board Member at Dentsply Sirona, NNN REIT, and Western Union; Member of Food Chain Advisory Board at Paine Schwartz Partners | Director since May 2023, previously Co-CEO of Kraft Foods and Senior Advisor to McKinsey & Company. | |
Joseph J. Wolk Board | Director | EVP and CFO at Johnson & Johnson; Board Member at St. Joseph\u2019s University and Stanford Medicine Board of Fellows | Director since May 2023, currently EVP and CFO at Johnson & Johnson, with extensive experience in finance and operations. | |
Larry J. Merlo Board | Chair of the Board | Chair of Budget Committee at University of Pittsburgh; Advisor to Korn Ferry and Charlesbank Capital Partners | Chair of Kenvue's Board since May 2023, previously President and CEO of CVS Health (2011-2021). | |
Melanie L. Healey Board | Director | Board Member at Hilton Worldwide Holdings, PPG Industries, and Verizon Communications | Director since May 2023, previously held senior leadership roles at Procter & Gamble, including Group President, North America. | |
Michael E. Sneed Board | Director | Board Member at Wayfair Inc., Thomas Jefferson University, Robert Wood Johnson Foundation, and WHYY | Director since May 2023, previously EVP, Global Corporate Affairs and Chief Communication Officer at Johnson & Johnson. | |
Richard E. Allison Jr. Board | Director | Board Member at Starbucks Corporation | Director since May 2023, previously CEO of Domino's Pizza and held leadership roles at Bain & Company. | |
Seemantini Godbole Board | Director | Member of IBM Advisory Board, Apparo\u2019s CXO Tech Council, and Charlotte Mecklenburg Community Foundation Board of Advisors | Director since May 2023, previously EVP, Chief Digital and Information Officer at Lowe's Companies, and held senior roles at Target, Sabre, and Travelocity. | |
Tamara S. Franklin Board | Director | Board Member at Genpact Limited, Dream Academy, and Arts Council of Princeton | Director since May 2023, previously Chief Digital, Data, and Analytics Officer at Marsh LLC and held leadership roles at IBM and Scripps Networks Interactive. | |
Vasant Prabhu Board | Director | Board Member at Delta Air Lines; Trustee at Brookings Institution | Director since May 2023, previously Vice Chairman and CFO of Visa Inc. and held leadership roles at NBCUniversal, Starwood Hotels, and Safeway. |
-
Given that the recovery of your Skin Health and Beauty segment is not expected to be linear, what specific strategies are you employing to accelerate growth in this area for 2025, and how will you adapt if consumer sentiment in key markets like Asia does not improve?
-
With significant investments in marketing and new partnerships, how are you ensuring that these efforts lead to sustainable sales growth and market share gains in a challenging category environment, rather than just short-term engagement?
-
Considering the anticipated reduction of commodity tailwinds and persistent inflationary pressures, how confident are you in achieving your long-term gross margin expansion targets, and what contingency plans are in place if input costs rise unexpectedly?
-
How are you addressing the risks associated with cautious retailer ordering patterns and potential store closures in key channels, particularly in the U.S. drug channel, to maintain product availability and consumer access?
-
As you focus on cost savings through the Vue Forward initiative while investing in brand growth, how do you ensure that cost reductions do not compromise your ability to innovate and drive growth in segments that are currently underperforming?
Research analysts who have asked questions during Kenvue earnings calls.
Andrea Teixeira
JPMorgan Chase & Co.
5 questions for KVUE
Bonnie Herzog
Goldman Sachs
5 questions for KVUE
Filippo Falorni
Citigroup Inc.
5 questions for KVUE
Peter Grom
UBS Group
5 questions for KVUE
Anna Lizzul
Bank of America Corporation
3 questions for KVUE
Javier Escalante Manzo
Evercore ISI
3 questions for KVUE
Korinne Wolfmeyer
Piper Sandler & Co.
3 questions for KVUE
Lauren Lieberman
Barclays
3 questions for KVUE
Nik Modi
RBC Capital Markets
3 questions for KVUE
Steve Powers
Deutsche Bank
3 questions for KVUE
Keith Devas
Jefferies Financial Group Inc.
2 questions for KVUE
Jeremy Fialko
HSBC
1 question for KVUE
Stephen Powers
Deutsche Bank
1 question for KVUE
Stephen Robert Powers
Deutsche Bank
1 question for KVUE
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Competes in the Self Care segment, which includes products like pain care, cough, cold, and allergy remedies, as well as digestive health, smoking cessation, and eye care. | |
Competes across multiple segments, including Self Care, Skin Health and Beauty, and Essential Health, with products in similar or adjacent categories. | |
Reckitt Benckiser Group | Competes in the Self Care segment, offering products in categories such as pain care and other over-the-counter remedies. |
Beiersdorf | Competes in the Skin Health and Beauty segment, focusing on face and body care products. |
L’Oréal | Competes in the Skin Health and Beauty segment, particularly in face and body care, as well as hair and sun care products. |
Competes in both the Skin Health and Beauty and Essential Health segments, offering products in categories like face and body care, oral care, and baby care. | |
Competes in the Essential Health segment, particularly in oral care products. | |
Competes in the Essential Health segment, offering products in categories like baby care and other essential health products. | |
Private-label brands | Compete across all segments, including Self Care, Skin Health and Beauty, and Essential Health, often offering generic or store-branded alternatives at lower prices. |
Recent press releases and 8-K filings for KVUE.
- Kimberly-Clark agreed to acquire Kenvue for an enterprise value of ~$48.7 billion, with Kenvue shareholders receiving $3.50 cash plus 0.14625 K-C shares per share (total consideration of $21.01/share).
- Post-close, K-C shareholders will own ~54% and Kenvue shareholders ~46% of the combined company.
- The deal carries a headline multiple of 14.3x Kenvue LTM Adjusted EBITDA (8.8x effective post-synergies), with fully committed financing targeting ~2.0x net leverage within 24 months.
- Expected synergies of ~$2.1 billion—including $1.9 billion in cost synergies and $0.2 billion in margin flow—drive value creation.
- Transaction is targeted to close in 2H 2026 subject to customary closing conditions and approvals.
- Combines Kimberly-Clark and Kenvue into a global health and wellness leader with pro forma annual revenues of $32 billion and $7 billion EBITDA.
- Deal valued at $48.7 billion, with Kenvue shareholders receiving $3.50 cash plus 0.14625 Kimberly-Clark shares per share (total $21.01), representing 4.3× LTM EBITDA (or 8.8× with $2.1 billion synergies).
- Targets $1.9 billion in cost synergies and $500 million in revenue synergies (net $2.1 billion EBITDA after reinvesting $300 million), to be achieved over 3-4 years, with one-time integration costs of $2.5 billion.
- Expected to close in H2 2026, subject to approvals; pro forma shareholders own 54% Kimberly-Clark and 46% Kenvue, with a leverage ratio goal of ~2× EBITDA within 24 months post-close.
- Kimberly-Clark and Kenvue will combine to form a $32 billion health and wellness leader generating approximately $7 billion in EBITDA pre-synergies and uniting 10 billion-dollar brands serving over a billion consumers globally.
- The transaction values Kenvue at about $48.7 billion, with Kenvue shareholders receiving $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share (total consideration of $21.01 per share).
- The companies expect to unlock $2.1 billion of annual EBITDA synergies net of reinvestment, including $1.9 billion in cost and $500 million in revenue synergies, reinvesting $300 million; cost synergies to be realized within three years and revenue synergies within four years.
- Financing is structured with the majority in stock, supplemented by $1.8 billion of net proceeds from the Suzano JV to fund the cash component; the combined company targets a ~2× leverage ratio within 24 months and expects mid-single-digit EPS dilution in year one, turning accretive in year two.
- The deal is expected to close in H2 2026 subject to regulatory and shareholder approvals; pro forma ownership will be ~54% Kimberly-Clark and ~46% Kenvue, with three Kenvue directors joining Kimberly-Clark’s board.
- Kimberly-Clark will acquire Kenvue for approximately $48.7 billion, with Kenvue shareholders receiving $3.50 cash & 0.14625 KC shares per share (≈$21.01/sh).
- The combined entity will have pro forma net revenues of $32 billion and $7 billion EBITDA, with 10 billion-dollar brands and target $2.1 billion of net annual EBITDA synergies (≈$1.9 billion cost + $0.5 billion revenue, net of $0.3 billion reinvestment) within 3–4 years.
- Financial guidance includes mid-single-digit EPS dilution in year 1 and accretion in year 2, with a target leverage of ~2× EBITDA within 24 months post-close, funded in part by proceeds from the Suzano joint venture; closing expected H2 2026 subject to approvals.
- Transaction unites Kimberly-Clark’s operational & commercial engine with Kenvue’s consumer health brands across baby care, women’s health, and active aging to form a leading pure-play global health & wellness company.
- Kimberly-Clark will acquire Kenvue for an enterprise value of $48.7 billion, offering $3.50 cash plus 0.14625 Kimberly-Clark shares per Kenvue share (total $21.01 per share).
- The combined company is projected to generate ~$32 billion in 2025 net revenues and ~$7 billion in adjusted EBITDA.
- Expected run-rate synergies of $2.1 billion (cost synergies ~$1.9 billion; revenue synergies ~$0.5 billion) with ~$2.5 billion in implementation costs; accretive to adjusted EPS by Year 2.
- Closing anticipated in 2H 2026, with pro forma ownership of ~54% for current Kimberly-Clark and ~46% for Kenvue shareholders.
- Kenvue Inc. reported third-quarter net sales decreased 3.5% year-over-year, driven by an organic sales decline of 4.4%.
- Gross profit margin expanded to 59.1% (adjusted 61.2%), while operating income margin was 16.7% (adjusted 21.5%).
- Diluted EPS was $0.21 versus $0.20 in the prior-year period; adjusted diluted EPS remained at $0.28.
- The company affirmed its full-year 2025 outlook and appointed Kirk Perry as permanent CEO.
- Kenvue, spun off from Johnson & Johnson in May 2023, generates over $15 billion in annual revenue with a $31.17 billion market cap but faces a 12.3% decline in one-year earnings growth and an Altman Z-Score signaling financial risk.
- In Q1 2025, Kenvue launched a multi-year collaboration with Albert Invent to integrate its AI platform—trained on 15 million molecular structures and 50,000 raw materials—into global R&D processes.
- The partnership will streamline product development and automate lab workflows by suggesting ingredient formulations (e.g., viscosity, fragrance, price) to improve safety, performance, and efficiency.
- This initiative is a core element of Kenvue’s broader digital transformation strategy to maintain leadership in the competitive consumer health market.
- Interim CEO Kirk Perry and CMO Caroline Tillett engaged Health Secretary Robert F. Kennedy Jr. to argue there’s no evidence linking acetaminophen during pregnancy to autism.
- Kenvue underscores Tylenol’s safety, citing lack of alternatives for pregnant women and FDA statements finding no definitive harm when used properly.
- The company is preparing for a critical Department of Health and Human Services report and has mounted a robust defense to keep Tylenol off any list citing it as an autism cause.
- Analysts rate the stock as Hold with an average one-year price target of $22.47 (upside 19.22%).
- Kenvue appointed Kirk Perry as interim CEO and Amit Banati as CFO (three months into role), while the board initiated a comprehensive strategic alternatives review to unlock shareholder value.
- Q2 organic sales declined 4.2%, driven by execution shortfalls, seasonal and customer inventory dynamics; segment declines included Self Care –5.9%, Skin Health & Beauty –3.7%, and Essential Health –2.4% despite positive global consumption trends.
- Adjusted operating margin contracted by 10 bps to 22.7%, and adjusted EPS was $0.29 versus $0.32 in Q2 2024.
- The company revised its 2025 guidance to expect organic sales down low-single digits and full-year adjusted EPS in the range of $1.00–$1.05, including a low-single-digit currency drag.
- Management outlined four immediate priorities—strengthening leadership, simplifying the operating model, flawless execution, and optimizing structure—to drive improved operational performance.
- Kenvue has completed its separation from J&J and is focused on transforming its operating model to drive profitable growth, including disentangling over 2300 TSAs and ramping up investments in brands and talent.
- The company is emphasizing its "five extraordinary powers" through robust innovation, marketing campaigns, and supply chain adjustments to capture market share across key regions.
- Management highlighted challenges from macroeconomic pressures and retail destocking, while noting a positive outlook for the second half as negative factors like tariffs and seasonal delays wane.